Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs-Reference-Cited by-同舟云学术

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs

Published:2023-03 Issue: Volume:58 Page:101013
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Girmenia Corrado,Barcellini Wilma,Bianchi Paola,Di Bona Eros,Iori Anna Paola,Notaro Rosario,Sica Simona,Zanella Alberto,De Vivo Antonio,Barosi Giovanni,Risitano Antonio

Funder

Alexion Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference71 articles.

1. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival;Kelly;Blood.,2011

2. High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine;McNamara;MMWR Morb Mortal Wkly Rep,2017

3. European Society for Immunodeficiencies (ESID) and European reference network on rare primary immunodeficiency, autoinflammatory and autoimmune diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management;Brodszki;J Clin Immunol,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fatal Neutropenic Enterocolitis in a Young Female After the First Round of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria;Cureus;2024-09-10

2. Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity;Frontiers in Immunology;2024-05-10

3. Disseminated Cryptococcosis Post Eculizumab Therapy: A Case Report and Literature Review;Cureus;2024-04-23

4. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy;International Journal of Laboratory Hematology;2024-04-15

5. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions;International Journal of Molecular Sciences;2024-03-22